Rheumatoid Arthritis stem cell therapy — your questions answered (2026)

About stem cell therapy for Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a systemic inflammatory autoimmune disease that can damage joints and other organs. MSC and other cell products are investigated for immune modulation, but they are distinct from disease-modifying antirheumatic drugs (DMARDs) and do not have established ability to reverse structural joint damage. Autologous origin, local injection or an anti-inflammatory laboratory signal does not prove clinical efficacy.

The evidence for Rheumatoid Arthritis

Human studies of cell products are heterogeneous and should be assessed by exact source, processing, dose, route, RA activity, background DMARDs, comparator and validated outcomes. The NIAMS RA treatment overview describes early use of DMARDs, biologic or targeted therapies, monitoring, rehabilitation and surgery where appropriate. A cell trial must not be used to delay effective control of inflammation.

Compare the full cost of an investigational product with continuing rheumatology care, monitoring and established medicines rather than an advertised injection price. Clarify who pays for product, imaging, laboratory tests, travel, follow-up, infection assessment and complications, and preserve access to DMARDs.

Can stem cells help rheumatoid arthritis?

Cell therapy for Rheumatoid Arthritis may be offered as an individualised programme, but regulatory status depends on the product, processing, indication and jurisdiction. It is currently investigational. Verify authorisation status, cell source, release testing and clinical evidence for the specific proposal.

Will I stop my medication?

Schedules vary by the exact product, protocol, route, monitoring needs and clinical context. Request the proposed schedule and its evidence before making travel arrangements.

How long does relief last?

Eligibility depends on the protocol's inclusion and exclusion criteria and an appropriately qualified clinician's assessment. An online checklist cannot determine candidacy or replace medical advice.

EU cost?

The partner-published indicative range for an Rheumatoid Arthritis programme is €3,000–€8,000 for treatment. Request a current written quotation and compare product, dose, visits, inclusions and follow-up before using country ranges as a benchmark.

Sources & further reading

We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.

• Open clinical trials for Rheumatoid Arthritis (ClinicalTrials.gov) ↗
• Peer-reviewed research on PubMed ↗
• ISSCR patient guide — what to ask ↗
• FDA consumer warning on stem-cell therapies ↗
• EMA — advanced-therapy (ATMP) framework ↗
• Clinic perspective — Stem Plus on Rheumatoid Arthritis ↗

← Back to Rheumatoid Arthritis overview · Rheumatoid Arthritis cost →